Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.45 |
| ▸ | POLQ | O75417 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 4/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905364 | 0.88 | TACR1 (0.57) | TACR1L3MBTL1CYP1A2SMOGPBAR1 | |
| SCHEMBL905379 | 0.87 | CYP1A2 (0.54) | TACR1CYP1A2CNR2PIK3CD | |
| SCHEMBL7137826 | 0.86 | TACR1 (0.47) | TACR1L3MBTL1CYP1A2SMOGPBAR1 | |
| SCHEMBL4672291 | 0.84 | TACR1 (0.43) | TACR1L3MBTL1SMO | |
| SCHEMBL905365 | 0.83 | TACR1 (0.49) | TACR1L3MBTL1PTPN11CYP1A2SMO | |
| SCHEMBL905329 | 0.81 | CKS1B (0.48) | TACR1PTPN11SMO | |
| SCHEMBL4374064 | 0.80 | CYP1A2 (0.41) | TACR1CYP1A2CNR2SMOGPBAR1 | |
| SCHEMBL905356 | 0.80 | TACR1 (0.44) | TACR1L3MBTL1SMO | |
| SCHEMBL6286992 | 0.80 | PTPN11 (0.50) | PTPN11 | |
| SCHEMBL4374612 | 0.78 | TACR1 (0.43) | TACR1L3MBTL1CNR2SMOGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1394150-B1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-1303490-B1 | N-OXIDES AS NK1 RECEPTOR ANTAGONIST PRODRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| EP-1776342-A1 | PROCESS FOR PREPARING CARBOXAMIDE PYRIDINE DERIVATIVES USED AS INTERMEDIATES IN THE SYNTHESIS OF NK-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006002860-A1 | PROCESS FOR PREPARING CARBOXAMIDE PYRIDINE DERIVATIVES USED AS INTERMEDIATES IN THE SYNTHESIS OF NK-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-12 | — | — | WO | disclosed |
| US-6897226-B2 | NK-1 receptor active amine oxide prodrugs | HOFFMANN-LA ROCHE INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-6806370-B2 | NEUROKININ-1 RECEPTOR ANTAGONISTS ARE FURTHER USEFUL FOR THE TREATMENT OF MOTION SICKNESS AND FOR TREATMENT INDUCED VOMITING | HOFFMANN-LA ROCHE INC. | 2004-10-19 | — | — | US | disclosed |
| US-6747026-B2 | FOR THERAPY OF DISEASE RESPONSIVE TO ANTAGONIST MODULATION OF THE NEUROKININ-1 (NK-1) RECEPTOR IN A PATIENT | HOFFMAN-LA ROCHE INC. | 2004-06-08 | — | — | US | disclosed |
| US-20040048901-A1 | NK-1 receptor active amine oxide prodrugs | HOFFMANN TORSTEN (DE) | 2004-03-11 | — | — | US | disclosed |
| EP-1394150-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| US-20040014793-A1 | NK-1 receptor active amine oxide prodrugs | HOFFMANN TORSTEN (DE) | 2004-01-22 | — | — | US | disclosed |
| US-20030149039-A1 | For therapy of disease responsive to antagonist modulation of the Neurokinin-1 (NK-1) receptor in a patient | HOFFMANN TORSTEN (DE) | 2003-08-07 | — | — | US | disclosed |
| US-6593472-B2 | Antiinflammatory, -arthritic and -emetic agents; central nervous system disorders; Parkinson's disease; antidepressants; psychological disorders; anxiolytic agents; antagonists of substance P receptors | HOFFMAN-LA ROCHE INC. | 2003-07-15 | — | — | US | disclosed |
| EP-1303490-A1 | N-OXIDES AS NK1 RECEPTOR ANTAGONIST PRODRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-6479483-B2 | 3,4,6-SUBSTITUTED PYRIDINE DERIVATIVES USEFUL FOR TREATING DEPRESSION AND PAIN, RESULTING FROM INFLAMMATORY CONDITIONS, SUCH AS MIGRAINE, RHEUMATOID ARTHRITIS, ASTHMA AND INFLAMATORY BOWEL DISEASE; NK1 RECEPTOR ANTAGONIST | HOFFMANN-LA ROCHE INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | BOS MICHAEL (CA) | 2002-07-11 | — | — | US | disclosed |
| US-20020045642-A1 | NK-1 receptor active amine oxide prodrugs | HOFFMANN-LA ROCHE INC. | 2002-04-18 | — | — | US | disclosed |
| WO-2002006236-A1 | N-OXIDES AS NK1 RECEPTOR ANTAGONIST PRODRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
| US-6297375-B1 | 4-phenyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1035115-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048901-A1 | NK-1 receptor active amine oxide prodrugs | TACR1, BDKRB1, NPSR1 | TACR1 1/4885POLQ 4639/4885L3MBTL1 2819/4885 |
| US-20040014793-A1 | NK-1 receptor active amine oxide prodrugs | TACR1, BDKRB1, NPSR1 | TACR1 1/4885POLQ 4639/4885L3MBTL1 2819/4885 |
| US-20030149039-A1 | For therapy of disease responsive to antagonist modulation of the Neurokinin-1 (NK-1) receptor in a patient | BDKRB2, BDKRB1, TACR1 | TACR1 3/4885POLQ 4709/4885L3MBTL1 2004/4885 |
| US-20020045642-A1 | NK-1 receptor active amine oxide prodrugs | TACR1, BDKRB1, NPSR1 | TACR1 1/4885POLQ 4639/4885L3MBTL1 2819/4885 |
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | CBR1, CBR3, HCCS | TACR1 534/4885POLQ 1658/4885L3MBTL1 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.